The company is reported to be cutting and moving up to 4,000 jobs.
168 employees will be pink-slipped this quarter.
The company will be beefing up support of Sandoz, its generics division.
Galderma's reorg will mean fewer employees. Novartis is closing a Canadian plant.
Actavis shrinks its staff by 30%, and Bayer reduces its California footprint.
The cutbacks will leave a staff of eight.
The company announced the layoffs Friday.
The company's pursuit of a tighter research focus follows a path very much like that of its peers.
Novartis is cutting jobs in California and adding some in Massachusetts, while Shire is trimming its UK R&D staff.
The news is part of an ongoing reorg by the Swiss firm that is rumored to include selling off its animal health business.
Generic giant Teva refuted allegations that the CEO, Jeremy Levin, and the board of directors were at odds over the company's cost-saving maneuvers.
The generics giant said it will lay off about 5,000 employees as it braces for the expiry of one of its specialty brands.
Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.
Akorn expands, buying Hi-Tech Pharmacal; nursing homes miss their goal to curb antipsychotic-drug use; Bayer cancer drug gets priority review; and Lonza lays off staff
J&J sells off its feminine side; Manhattan Research's study on the sales rep "tablet dance"; Cepheid rolls out a consumer TB campaign; and healthcare sector job losses top out in July.
Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.
Perrigo sweeps Elan off its feet for $8.6 billion, and Valeant is slashing 2,700 jobs.
Roger Perlmutter has begun to trim the fat off Merck's lackluster pipeline.
The drug maker eases the burden on its Symbicort franchise by scooping up Pearl for $510 million.